Antibody response to human papillomavirus vaccine in subjects with inherited bone marrow failure syndromes

Vaccine

Volumn 32, Issue 10, 2014, Pages 1169-1173

  Alter, Blanche P ^a   Giri, Neelam ^a   Pan, Yuanji ^b   Savage, Sharon A ^a   Pinto, Ligia A ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

Dyskeratosis congenita; Fanconi anemia; Human papillomavirus; Inherited bone marrow failure syndromes; Vaccine

Indexed keywords

DYSKERATOSIS CONGENITA; FANCONI ANEMIA; HUMAN PAPILLOMAVIRUS; INHERITED BONE MARROW FAILURE SYNDROMES; VACCINE;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FANCONI ANEMIA; FEMALE; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; YOUNG ADULT;

EID: 84893946909     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.11.048     Document Type: Article

References (18)

1. Alter B.P., Giri N., Savage S.A., et al. Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. Br. J. Haematol. 2010 July, 150(2):179-188.
2. Munoz N., Bosch F.X., Castellsague X., et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int. J. Cancer 2004 Aug 20, 111(2):278-285.
3. Forman D., de M.C., Lacey C.J., et al. Global burden of human papillomavirus and related diseases. Vaccine 2012 Nov 20, 30(Suppl.5):F12-F23.
4. Schiffman M., Castle P.E., Jeronimo J., Rodriguez A.C., Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007 Sep 8, 370(9590):890-907.
5. Kreimer A.R., Clifford G.M., Boyle P., Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol. Biomarkers Prev. 2005 Feb, 14(2):467-475.
6. Chaturvedi A.K. Epidemiology and clinical aspects of HPV in head and neck cancers. Head Neck Pathol. 2012 July, 6(Suppl. 1):S16-S24.
7. Lingen M.W., Xiao W., Schmidt A., et al. Low etiologic fraction for high-risk human papillomavirus in oral cavity squamous cell carcinomas. Oral Oncol. 2012 Jul 27.
8. Gillison M.L., Chaturvedi A.K., Lowy D.R. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 2008 Nov 15, 113(Suppl. 10):46-3036.
9. Kutler D.I., Auerbach A.D., Satagopan J., et al. High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch. Otolaryngol. Head Neck Surg. 2003, 129:106-112.
10. van Zeeburg H.J., Snijders P.J., Wu T., et al. Clinical and molecular characteristics of squamous cell carcinomas from Fanconi anemia patients. J. Natl. Cancer Inst. 2008 Nov 19, 100(22):53-1649.
11. Alter B.P., Giri N., Savage S.A., Quint W.G., de Koning M.N., Schiffman M. Squamous cell carcinomas in patients with Fanconi anemia and dyskeratosis congenita: a search for human papillomavirus. Int. J. Cancer 2013 Sep 15, 133(6):5-1513.
12. HPV vaccine recommendations Pediatrics Mar 2012, 129(3):602-605.
13. Fagerlie S.R., Bagby G.C. Immune defects in Fanconi anemia. Crit. Rev. Immunol. 2006, 26(1):81-96.
14. Khan S., Pereira J., Darbyshire P.J., et al. Do ribosomopathies explain some cases of common variable immunodeficiency?. Clin. Exp. Immunol. Jan 2011, 163(1):96-103.
15. Dauner J.G., Pan Y., Hildesheim A., Harro C., Pinto L.A. Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine. Vaccine 2010 July 26, 28(33):13-5407.
16. Dessy F.J., Giannini S.L., Bougelet C.A., et al. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum.Vaccin. Nov 2008, 4(6):425-434.
17. Einstein M.H., Baron M., Levin M.J., et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum. Vaccin. 2011 Dec 1, 7(12):58-1343.
18. Schiller J.T., Castellsague X., Garland S.M. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012 Nov 20, 30(Suppl.5):F123-F138.